Company · Education
Auckland
Every investor coverage indicates participated in a round University of Auckland raised.
Companies University of Auckland acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Greg O'Grady | Professor of Surgery | SmartCompany |
| Professor Rod Dunbar | Professor | Brandon Capital portfolio |
Stories naming University of Auckland. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
MA Financial Group announces the appointment of Professor David Lloyd as an independent director to its board, effective 21 August 2026, citing his governance and leadership experience.
Roundup of three ANZ raises: BlueNexus' $2m seed led by M31 Capital, Hyades' NZ$1.1m pre-seed with Icehouse Ventures plus an R&D grant, and ESGAgent.ai's $725,000 seed led by DNX Ventures.
Round-up reporting Neara's $45 million Series C, Alimetry's US$18 million Series A2, Earthodic's US$4 million seed, and Antler's latest residency intake of startups each receiving $225,000 for 12% stakes.
Also Startup Daily
Auckland University spinout TamoRx has secured NZ$15.25 million to develop a new cancer immunotherapy, in a round led by Brandon Capital alongside the university's Inventors' Fund, with a Callaghan Innovation grant included.
Biotech Proacta's release: its Phase I cancer-drug trial is underway, and Alta Partners' new funding tops the Series A up to $12M alongside lead backer GBS Ventures; Alta's David Mack joins the board.